Components of Placebo Effect: Randomised Controlled Trial in Patients with Irritable Bowel Syndrome

被引:0
|
作者
Hummelsberger, J. [1 ]
机构
[1] Chinese Med SMS Societas Med Sinensis, Int Soc, Hackenstr 7 C, D-80331 Munich, Germany
来源
DEUTSCHE ZEITSCHRIFT FUR AKUPUNKTUR | 2010年 / 53卷 / 02期
关键词
D O I
10.1016/j.dza.2010.04.011
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objective: To investigate whether placebo effects can experimentally be separated into the response to three components - assessment and observation, a therapeutic ritual (placebo treatment), and a supportive patient- practitioner relationship - and then progressively combined to produce incremental clinical improvement in patients with irritable bowel syndrome. To assess the relative magnitude of these components. Design: A six week single blind three arm randomised controlled trial. Setting Academic medical centre. Participants 262 adults (76 % women), mean (SD) age 39 (14), diagnosed by Rome II criteria for and with a score of >= 150 on the symptom severity scale. Interventions: For three weeks either waiting list (observation), placebo acupuncture alone ("limited"), or placebo acupuncture with a patient- practitioner relationship augmented by warmth, attention, and confidence ("augmented"). At three weeks, half of the patients were randomly assigned to continue in their originally assigned group for an additional three weeks. Main outcome measures Global improvement scale (range 1-7), adequate relief of symptoms, symptom severity score, and quality of life. Results: At three weeks, scores on the global improvement scale were 3.8 (SD 1.0) v 4.3 (SD 1.4) v 5.0 (SD 1.3) for waiting list versus "limited" versus "augmented," respectively (P < 0.001 for trend). The proportion of patients reporting adequate relief showed a similar pattern: 28 % on waiting list, 44 % in limited group, and 62 % in augmented group (P < 0.001 for trend). The same trend in response existed in symptom severity score (30 (63) v 42 (67) v 82 (89), P < 0.001) and quality of life (3.6 (8.1) v 4.1 (9.4) v 9.3 (14.0), P < 0.001). All pairwise comparisons between augmented and limited patient- practitioner relationship were significant: global improvement scale (P < 0.001), adequate relief of symptoms (P < 0.001), symptom severity score (P = 0.007), quality of life (P = 0.01). Results were similar at six week follow-up. Conclusion Factors contributing to the placebo effect can be progressively combined in a manner resembling a graded dose escalation of component parts. Non-specific effects can produce statistically and clinically significant outcomes and the patient- practitioner relationship is the most robust component.
引用
收藏
页码:41 / 42
页数:3
相关论文
共 50 条
  • [41] Long-term treatment with probiotics in primary care patients with irritable bowel syndrome - a randomised, double-blind, placebo controlled trial
    Begtrup, Luise Molenberg
    de Muckadell, Ove B. Schaffalitzky
    Kjeldsen, Jens
    Christensen, Rene dePont
    Jarbol, Dorte Ejg
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2013, 48 (10) : 1127 - 1135
  • [42] Determination of placebo effect in irritable bowel syndrome
    Enck, P
    Klosterhalfen, S
    Kruls, W
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2005, 130 (34-35) : 1934 - 1937
  • [43] Placebo responses in patients with irritable bowel syndrome
    Nedelcu, L.
    PSYCHOLOGY & HEALTH, 2010, 25 : 285 - 286
  • [44] Peppermint Oil Treatment for Irritable Bowel Syndrome: A Randomized Placebo-Controlled Trial
    Nee, Judy
    Ballou, Sarah
    Kelley, John M.
    Kaptchuk, Ted J.
    Hirsch, William
    Katon, Jesse
    Cheng, Vivian
    Rangan, Vikram
    Lembo, Anthony
    Iturrino, Johanna
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 (11): : 2279 - 2285
  • [45] FECAL MICROBIOTA TRANSPLANTATION IN IRRITABLE BOWEL SYNDROME AND A RANDOMIZED PLACEBO-CONTROLLED TRIAL
    Holster, Savanne
    Brummer, Robert J.
    Repsilber, Dirk
    Konig, Julia
    GASTROENTEROLOGY, 2017, 152 (05) : S101 - S102
  • [46] A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome
    Efskind, PS
    Bernklev, T
    Vatn, MH
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1996, 31 (05) : 463 - 468
  • [47] Pilot study: a randomised, double blind, placebo controlled trial of pancrealipase for the treatment of postprandial irritable bowel syndrome-diarrhoea
    Money, Mary E.
    Walkowiak, Jaroslaw
    Virgilio, Chris
    Talley, Nicholas J.
    FRONTLINE GASTROENTEROLOGY, 2011, 2 (01) : 48 - 56
  • [48] Alverine citrate (Spasmonal) fails to relieve the symptoms of irritable bowel syndrome: Results of a double blind, randomised placebo controlled trial
    Mitchell, SA
    Mee, AS
    Palmer, KR
    Chapman, RW
    GUT, 2001, 48 : A46 - A46
  • [49] A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial
    Solveig C Ligaarden
    Lars Axelsson
    Kristine Naterstad
    Stian Lydersen
    Per G Farup
    BMC Gastroenterology, 10
  • [50] Acupuncture for irritable bowel syndrome: primary care based pragmatic randomised controlled trial
    Hugh MacPherson
    Helen Tilbrook
    J Martin Bland
    Karen Bloor
    Sally Brabyn
    Helen Cox
    Arthur Ricky Kang’ombe
    Mei-See Man
    Tracy Stuardi
    David Torgerson
    Ian Watt
    Peter Whorwell
    BMC Gastroenterology, 12